US 10889813
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
granted A61KA61K31/713A61K47/549
Quick answer
US patent 10889813 (Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/713, A61K47/549, A61K47/56, A61P